Jenburkt Pharmaceuticals Ltd (JENBURPH)

Loading page…

Jenburkt Pharmaceuticals Ltd (JENBURPH) · mywealthgrid

About

Jenburkt Pharmaceuticals Ltd is a mid-cap pharma company (₹459.84 Cr market cap) listed on BSE, operating in the pharmaceuticals & biotechnology segment. Quarterly revenue ranges ₹17–34 Cr, with operating margins historically in the 17–26% range, positioning it as a smaller player in India's competitive generic and branded pharmaceutical landscape.

Face value: ₹10

Market cap

₹403 Cr

P/E

24.4×

P/B

2.3×

Dividend yield

2.3%

ROE

20.2%

ROCE

27.2%

Debt / equity

0.01

OPM

26.6%

EPS (TTM)

₹37.4

Book value

₹389.5

52-week high

—

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

Operating margin compressed from 22.06% (Dec 2020) to 17.02% (Mar 2021), signaling cost pressure or mix deterioration; verify whether this is temporary or structural. - Revenue volatility: Q2 FY2020 collapsed to ₹17.43 Cr from ₹30–34 Cr range, indicating exposure to disruptions (supply, regulatory, or demand) — verify root cause and recurrence risk. - Stock fell 12.6% over 12 months despite consistent dividend payouts, and trades at PE 27.86; assess whether valuation is pricing in near-term headwinds or if institutional absence (FII 0%, DII 0.12%) signals unresolved concerns. - Indian generic pharmaceutical sector faces price compression and regulatory scrutiny; verify the company's exposure to price-controlled segments and compliance costs.

Generated analysis · source review pending

Growth drivers

ROE of 20.25% indicates capital is being deployed efficiently; organic growth funded from retained earnings is viable if this level sustains. - D/E ratio of 0.01 provides balance-sheet headroom to fund expansion through debt without leverage; verify whether management plans organic capex or M&A. - Operating margins historically reached 26.63%; recovery toward that level via cost control or favorable product mix would expand earnings without volume growth. - Consistent dividend payments since 2021 signal steady cash generation; verify if distributions constrain reinvestment or if free cash flow supports both.

Generated analysis · source review pending

2,177 historical price candles were omitted because the exchange source has not been verified.

₹915.3-0.9%1Y

Quick read

rule-based

Pros

+Strong return on equity of 20.1% (3-yr avg)
+High return on capital employed of 26.6%
+Healthy operating margin of 26.6%
+Profit CAGR of 16.6% over the last 5 years
+Almost debt-free (debt/equity 0)
+Comfortable interest coverage of 98.6×
+Dividend payout of 55.2% of profit

Cons

−Modest revenue growth of 5% a year over the last 5 years

Research score

Structured signal from quality, growth, valuation and momentum.

54/100

Business quality: 81
Growth

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Standalone figures · ₹ crore · years without a filed annual are summed from quarters

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
	93	103	115	123	119	109	124	137	142	152
COGS	-28	-32	-36	-36	-33	30	31	33	30	30
Gross profit	—	—	—	—	—	79	93	104	112	122
	105	116	127	134	132	59	65	73	78	82
Operating profit (EBITDA)	16	20	24	25	20	20	27	30	33	40
OPM %	17%	18.9%	20.7%	20.4%	16.6%	18.2%	22%	22.2%	23.3%	26.6%
Depreciation	2	2	2	1	2	2	2	2	2	3
Interest	0	0	0	0	1	0	0	0	0	0
	3	3	3	3	4	4	5	5	5	7
Profit before tax	17	20	25	27	21	22	30	33	35	44
Tax	6	7	8	7	6	5	8	8	9	12
Tax %	36%	34.1%	31.9%	25.7%	29.6%	23.8%	25.3%	25.1%	26.2%	27%
	11	13	17	20	15	17	22	25	26	32
PAT margin %	11.6%	13.1%	15%	16.1%	12.5%	15.1%	18%	18%	18.3%	21.1%
EPS (₹)	23.2	29	—	43.1	32.4	36	48.6	53.9	58.9	72.7
EPS adjusted (₹)	—	—	—	—	32.4	36	48.6	55.8	58.9	72.7
	31.1%	28%	—	23.6%	25%	28.4%	24.7%	26.7%	26%	24.8%
Annual report	Annual report for Mar 2016	Annual report for Mar 2017	Annual report for Mar 2018	Annual report for Mar 2019	Annual report for Mar 2020	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025

₹ Cr	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity capital	5	5	5	4	4	4
Reserves	—	94	113	118	141	167
Minority interest	—	—	—	—	—	0
	—	4	6	2	0	2
	—	19	20	17	20	22
Total equity & liabilities	—	121	143	142	165	196
	12	11	11	10	10	15
CWIP	—	0	0	1	1	40
Investments	—	7	8	11	17	21
	—	104	123	119	137	121
Total assets	—	121	143	142	165	196

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
	19	9	17	8	28
	-19	-1	3	-1	-17
	-1	-6	-21	-7	-8
Net cash flow	-0	3	-1	0	3
Free cash flow	18	6	15	6	8
CFO / Operating profit %	98%	34%	56.1%	24.5%	69.1%

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Standalone figures

Ratio	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Margins
Gross margin %	—	—	—	72.5%	74.6%	75.9%	78.6%	80.5%
EBITDA margin %	20.7%	20.4%	16.6%	18.2%	22%	22.2%	23.3%	26.6%
EBIT margin %	19.4%	19.3%	14.7%	16.3%	20.4%	20.6%	21.7%	24.8%
PAT margin %	15%	16.1%	12.5%	15.1%	18%	18%	18.3%	21.1%
Working capital
Receivable days	—	—	—	47	45	45	50	50
Inventory days	—	—	—	92	115	92	103	109
Payable days	—	—	—	56	83	67	75	100
NWC days	—	—	—	83	77	70	78	59
Leverage
Current ratio	—	—	—	4.45	3.57	5.15	6.7	3
Debt to EBITDA	—	—	—	0.19	0.21	0.08	0	0.05
Debt to equity	—	—	—	0.04	0.05	0.02	0	0.01
Interest coverage	62.6	69.3	40.9	47	70.5	89.8	131.3	98.6
Asset turnover	—	—	—	0.9	0.87	0.96	0.86	0.77
Return ratios
Return on assets %	—	—	—	13.6%	15.6%	17.4%	15.7%	16.3%
Return on capital employed %	—	—	—	21.4%	27%	26.8%	25.8%	27.2%
Return on equity %	—	—	—	16.8%	19%	20.1%	17.9%	18.7%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	47.42%	47.39%	47.23%	46.71%	46.71%	46.69%	46.68%	46.67%	46.66%	46.65%	46.64%	46.62%
FII	1.38%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	0%	0%	0%	0%	0%	0.12%	0.12%	0.12%	0.12%	0.12%	0.12%	0.12%
	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	51.2%	52.61%	52.77%	53.29%	53.29%	53.19%	53.2%	53.21%	53.22%	53.23%	53.24%	53.26%
No. of shareholders	—	—	—	—	—	—	—	—	6,855	7,163	6,999	7,103

Promoter holding down 0.8 percentage points since Sep 2023.

1 deal · 6 Jan 2023 – 6 Jan 2023

Date	Client	Type	Venue	Side	Quantity	Price	Value
6 Jan 2023	JENBURKT PHARMACEUTICALS LTD	Bulk	BSE	Buy	47,037	₹649.97	₹3.06 Cr

1–1 of 1

1 / 1

Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.

Mr. ASHISH UTTAM BHUTAExecutive Director-Chairperson related to Promoter-MD
Mr. DILIP HARKISHANDAS BHUTAExecutive Director
Mrs. HINA RAVINDRA MEHTANon-Executive - Independent Director
Mr. SUMIT AJAYBHAI THAKKARNon-Executive - Independent Director
Mr. KRISHNAN SUBHARAMANNon-Executive - Independent Director
Mr. PANKAJ ARUN DANTWALANon-Executive - Independent Director
Ashish R ShahCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Jenburkt Pharmaceuticals Ltd. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

22

Final dividend28 Aug 2026 · ex-date₹20.7
Final dividend11 Jul 2025 · ex-date₹18
Dividend dividend23 Jul 2024 · ex-date₹15.3
Dividend dividend19 Jul 2023 · ex-date₹14.4
Final dividend21 Jul 2022 · ex-date₹12
Dividend dividend30 Aug 2021 · ex-date₹10.2
Interim dividend18 Mar 2020 · ex-date₹8.1
Final dividend22 Jul 2019 · ex-date₹10.2
Final dividend23 Jul 2018 · ex-date₹6
Interim dividend27 Mar 2018 · ex-date₹3
Dividend dividend21 Jul 2017 · ex-date₹8.1
Dividend dividend19 Jul 2016 · ex-date₹0.9
Interim dividend17 Mar 2016 · ex-date₹6.3
Dividend dividend31 Aug 2015 · ex-date₹6.3
Dividend dividend3 Sept 2014 · ex-date₹5.1
Dividend dividend18 Sept 2013 · ex-date₹4.2
Dividend dividend23 Jul 2012 · ex-date₹3.5
Dividend dividend21 Jul 2011 · ex-date₹3.5
Dividend dividend21 Jul 2010 · ex-date₹3
Dividend dividend23 Jul 2009 · ex-date₹1.8
Dividend dividend23 Jul 2008 · ex-date₹1.25
Dividend dividend18 Jul 2007 · ex-date₹1.25

1

Board meeting to consider results6 Aug 2026

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

47 announcementsExport CSV

22 Sept 2026, 1:20 pmCompany Update

Intimation Regarding Admission Of Equity Shares Of The Company Under 'Permitted To Trade' Category On National Stock Exchange Of India Limited.

General PDF

22 Sept 2026, 1:04 pmInsider Trading / SAST

Closure of Trading Window

Closure of Trading Window PDF

18 Sept 2026, 4:23 pmCompany Update

Announcement under Regulation 30 (LODR)-Change in Management

Change in Management PDF

4 Sept 2026, 9:34 pmCompany Update

Announcement under Regulation 30 (LODR)-Change in Directorate

Change in Directorate PDF

4 Sept 2026, 9:23 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Scrutinizer''s Report

AGM PDF

4 Sept 2026, 8:40 pmCompany Update

Proceedings Of The 41St Annual General Meeting Of The Company Held On Friday, 04Th September, 2026.

General PDF

4 Sept 2026, 8:35 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Outcome of AGM

AGM PDF

4 Sept 2026, 12:40 pmCompany Update

Announcement under Regulation 30 (LODR)-Change in Management

Change in Management PDF

Date	Category	Subject	Filing
22 Sept 2026, 1:20 pm	Company Update General	Intimation Regarding Admission Of Equity Shares Of The Company Under 'Permitted To Trade' Category On National Stock Exchange Of India Limited.	PDF
22 Sept 2026, 1:04 pm	Insider Trading / SAST Closure of Trading Window	Closure of Trading Window

Loading announcements…

Ratio	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Margins
Gross margin %	—	—	—	72.5%	74.6%	75.9%	78.6%	80.5%
EBITDA margin %	20.7%	20.4%	16.6%	18.2%	22%	22.2%	23.3%	26.6%
EBIT margin %	19.4%	19.3%	14.7%	16.3%	20.4%	20.6%	21.7%	24.8%
PAT margin %	15%	16.1%	12.5%	15.1%	18%	18%	18.3%	21.1%
Working capital
Receivable days	—	—	—	47	45	45	50	50
Inventory days	—	—	—	92	115	92	103	109
Payable days	—	—	—	56	83	67	75	100
NWC days	—	—	—	83	77	70	78	59
Leverage
Current ratio	—	—	—	4.45	3.57	5.15	6.7	3
Debt to EBITDA	—	—	—	0.19	0.21	0.08	0	0.05
Debt to equity	—	—	—	0.04	0.05	0.02	0	0.01
Interest coverage	62.6	69.3	40.9	47	70.5	89.8	131.3	98.6
Asset turnover	—	—	—	0.9	0.87	0.96	0.86	0.77
Return ratios
Return on assets %	—	—	—	13.6%	15.6%	17.4%	15.7%	16.3%
Return on capital employed %	—	—	—	21.4%	27%	26.8%	25.8%	27.2%
Return on equity %	—	—	—	16.8%	19%	20.1%	17.9%	18.7%

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Jenburkt Pharmaceuticals Ltd

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Events

22

1

Announcements

Not in the F&O segment

22

1

No fund holdings on record

Announcements

Annual reports

Compounded sales growth

Compounded profit growth

Return on equity

Jenburkt Pharmaceuticals Ltd

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Events

Dividends22

Board meetings1

Announcements

Not in the F&O segment

Dividends22

Board meetings1

Ratio timeline

Quarterly record

Bulk & block deals

Board and management

No fund holdings on record

Announcements

Annual reports

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

22

1

22

1